Published by Coherent Market Insights
Posted on October 4, 2021
Leukapheresis is basically a medical procedure used to treat patients with chronic lymphocytic leukemia or those with extremely high white blood cell count. Leukapheresis is a type of test performed in apheresis. In this procedure, white blood cells are removed including leukemia cells, and return the rest of the blood cells into the bloodstream. When a patient has a leukemia attack, the immune system begins to produce antibodies that attack the leukemic cells that have invaded the body. Once these cells are eliminated, the patient begins to show signs of recovery and may even be cured by some medications. The leukapheresis process is also used in research and development activities. This procedure is mostly performed on the patient suffering from leukemia.
Request For Sample Copy of This Premium Research Leukapheresis Market @
https://www.coherentmarketinsights.com/insight/request-sample/4142
The growing prevalence of incidence of leukemia around the globe is a prime factor fueling the market growth of leukapheresis. According to the National Cancer Institute, the rate of new cases of leukemia was 14.1 per 100,000 men and women per year. The death rate was 6.3 per 100,000 men and women per year. In 2017, there were an estimated 434,982 people living with leukemia in the United States. High demand for blood and blood components is also projected to foster market growth. Moreover, a growing number of clinical trials for the development of CAR-T therapy for leukemia is further projected to augment the market growth of the leukapheresis.
On the other hand, the high cost associated with the treatment of leukapheresis is expected to hinder the market growth over the forecast period.
North America is expected to gain significant growth over the forecast period and this is attributed to increasing healthcare expenditure in the region. According to the U.S. Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation’s Gross Domestic Product, health spending accounted for 17.7 percent. Also, the high presence of chronic disease in the region is further projected to foster market growth. According to the National Health Council, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country.2 By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.
In July 2020, Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus
(brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
In January 2020, Fresenius Kabi inaugurates €30 million expansion of transfusion and apheresis disposables plant in the Dominican Republic. These products are used, for example, to collect blood components such as platelets or plasma.
Major Players in Leukapheresis Market
Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Fresenius SE & Co. KGaA, BioIVT, Grifols, S.A, and Key Biologics, LLC.
Ask for PDF sample copy of the Leukapheresis market report @
https://www.coherentmarketinsights.com/insight/request-pdf/4142
Leukapheresis Market insights will improve the revenue impact of businesses in various industries:
• providing a framework tailored toward understanding the attractiveness quotient of various products/solutions/technologies in the Leukapheresis Market
• Guiding stakeholders to identify key problem areas pertaining to their consolidation strategies in the global Leukapheresis market and offers solutions
• assessing the impact of changing regulatory dynamics in the regions in which companies are keen on expanding their footprints
• provides an understanding of disruptive technology trends to help businesses make their transitions smoothly
• helping leading companies make strategy recalibrations ahead of their competitors and peers
• Offers insights into promising growth for top players aiming to retain their leadership position in the market & supply-side analysis of the Leukapheresis market.
Reasons to Purchase this Report
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4142
In conclusion, the Leukapheresis market report presents the descriptive analysis of the parent market supported elite players, present, past, and artistic movement information which is in a position to function as a profitable guide for all the Leukapheresis industry business competitors. Our expert research analyst’s team has been trained to supply in-depth marketing research reports from every individual sector which can be helpful to know the industry data within the most precise way.
Contact:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Leukapheresis Market – Increasing investments of blood donations activities by manufacturers is expected to boost the growth of the market appeared first on Gatorledger.
Leukapheresis is basically a medical procedure used to treat patients with chronic lymphocytic leukemia or those with extremely high white blood cell count. Leukapheresis is a type of test performed in apheresis. In this procedure, white blood cells are removed including leukemia cells, and return the rest of the blood cells into the bloodstream. When a patient has a leukemia attack, the immune system begins to produce antibodies that attack the leukemic cells that have invaded the body. Once these cells are eliminated, the patient begins to show signs of recovery and may even be cured by some medications. The leukapheresis process is also used in research and development activities. This procedure is mostly performed on the patient suffering from leukemia.
Request For Sample Copy of This Premium Research Leukapheresis Market @
https://www.coherentmarketinsights.com/insight/request-sample/4142
The growing prevalence of incidence of leukemia around the globe is a prime factor fueling the market growth of leukapheresis. According to the National Cancer Institute, the rate of new cases of leukemia was 14.1 per 100,000 men and women per year. The death rate was 6.3 per 100,000 men and women per year. In 2017, there were an estimated 434,982 people living with leukemia in the United States. High demand for blood and blood components is also projected to foster market growth. Moreover, a growing number of clinical trials for the development of CAR-T therapy for leukemia is further projected to augment the market growth of the leukapheresis.
On the other hand, the high cost associated with the treatment of leukapheresis is expected to hinder the market growth over the forecast period.
North America is expected to gain significant growth over the forecast period and this is attributed to increasing healthcare expenditure in the region. According to the U.S. Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation’s Gross Domestic Product, health spending accounted for 17.7 percent. Also, the high presence of chronic disease in the region is further projected to foster market growth. According to the National Health Council, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country.2 By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.
In July 2020, Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
In January 2020, Fresenius Kabi inaugurates €30 million expansion of transfusion and apheresis disposables plant in the Dominican Republic. These products are used, for example, to collect blood components such as platelets or plasma.
Major Players in Leukapheresis Market
Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Fresenius SE & Co. KGaA, BioIVT, Grifols, S.A, and Key Biologics, LLC.
Ask for PDF sample copy of the Leukapheresis market report @
https://www.coherentmarketinsights.com/insight/request-pdf/4142
Leukapheresis Market insights will improve the revenue impact of businesses in various industries:
• providing a framework tailored toward understanding the attractiveness quotient of various products/solutions/technologies in the Leukapheresis Market
• Guiding stakeholders to identify key problem areas pertaining to their consolidation strategies in the global Leukapheresis market and offers solutions
• assessing the impact of changing regulatory dynamics in the regions in which companies are keen on expanding their footprints
• provides an understanding of disruptive technology trends to help businesses make their transitions smoothly
• helping leading companies make strategy recalibrations ahead of their competitors and peers
• Offers insights into promising growth for top players aiming to retain their leadership position in the market & supply-side analysis of the Leukapheresis market.
Reasons to Purchase this Report
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4142
In conclusion, the Leukapheresis market report presents the descriptive analysis of the parent market supported elite players, present, past, and artistic movement information which is in a position to function as a profitable guide for all the Leukapheresis industry business competitors. Our expert research analyst’s team has been trained to supply in-depth marketing research reports from every individual sector which can be helpful to know the industry data within the most precise way.
Contact:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Leukapheresis Market – Increasing investments of blood donations activities by manufacturers is expected to boost the growth of the market appeared first on Gatorledger.
Explore more articles in the Research Reports category
